NO20053626L - Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose - Google Patents

Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose

Info

Publication number
NO20053626L
NO20053626L NO20053626A NO20053626A NO20053626L NO 20053626 L NO20053626 L NO 20053626L NO 20053626 A NO20053626 A NO 20053626A NO 20053626 A NO20053626 A NO 20053626A NO 20053626 L NO20053626 L NO 20053626L
Authority
NO
Norway
Prior art keywords
combination
progestin
estrogen
endomeriosis
treatment
Prior art date
Application number
NO20053626A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20053626L publication Critical patent/NO20053626L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20053626A 2003-02-05 2005-07-26 Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose NO20053626L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (fr) 2003-02-05 2004-02-03 Composition comportant une combinaison d'un inhibiteur de l'aromatase, d'une progestine et d'un oestrogene et son utilisation pour le traitement des endometrioses

Publications (1)

Publication Number Publication Date
NO20053626L true NO20053626L (no) 2005-08-26

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053626A NO20053626L (no) 2003-02-05 2005-07-26 Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose

Country Status (29)

Country Link
US (2) US7910570B2 (fr)
EP (2) EP1589976B1 (fr)
JP (2) JP4658918B2 (fr)
KR (1) KR101075929B1 (fr)
CN (1) CN100393360C (fr)
AR (1) AR043013A1 (fr)
AT (1) ATE374612T1 (fr)
AU (1) AU2004210184B2 (fr)
BR (1) BRPI0407039A (fr)
CA (1) CA2513910C (fr)
CO (1) CO5580789A2 (fr)
CY (1) CY1107816T1 (fr)
DE (1) DE602004009288T2 (fr)
DK (1) DK1589976T3 (fr)
ES (1) ES2293215T3 (fr)
GB (1) GB0302572D0 (fr)
IL (1) IL169583A0 (fr)
IS (1) IS2547B (fr)
MX (1) MXPA05008347A (fr)
MY (1) MY140723A (fr)
NO (1) NO20053626L (fr)
NZ (1) NZ541222A (fr)
PL (1) PL214680B1 (fr)
PT (1) PT1589976E (fr)
RU (2) RU2360681C2 (fr)
TW (1) TWI354556B (fr)
UA (1) UA80741C2 (fr)
WO (1) WO2004069260A1 (fr)
ZA (1) ZA200506221B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CN101107004A (zh) * 2004-10-04 2008-01-16 韦恩州立大学 芳香酶抑制剂在子宫内膜腔和子宫手术前的子宫薄化中的应用
WO2009075838A2 (fr) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Traitement de la ménorragie avec un inhibiteur de l'aromatase
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (fr) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant avec un noyau et un tube enrobant le noyau
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception
WO2024197239A1 (fr) * 2023-03-23 2024-09-26 William Bologna Compositions bioadhésives et procédé de traitement de l'endométriose avec des inhibiteurs d'aromatase sans augmentation de la production de gonadatropine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
TR200102867T2 (fr) 1998-06-11 2002-06-21 Endorecherchel@Inc
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2462081A1 (fr) 2000-10-11 2002-04-18 Laura Kragie Composition et procede destines a reduire les effets indesirables et/ou ameliorer l'efficacite d'agents inhibant l'aromatase
DE60214355T2 (de) 2001-01-26 2007-08-30 Pfizer Italia S.R.L. Exemestan zur behandlung von hormonabhängigen störungen
WO2002074315A1 (fr) 2001-03-21 2002-09-26 Schering Aktiengesellschaft Preparations pharmaceutiques combinees renfermant des inhibiteurs de l'aromatase et des substances a activite oestrogenique et leur utilisation dans la production d'un medicament pour l'oestrogenotherapie de substitution
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (fr) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
IL161630A0 (en) 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
JP2005518412A (ja) 2002-01-22 2005-06-23 アクゾ・ノベル・エヌ・ベー 内因性エストロゲンの合成を阻害する薬物の投与に伴う愁訴の治療におけるチボロン
AU2003213958A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
AU2003213956A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
CA2521305A1 (fr) 2002-04-03 2003-10-09 Jencap Research Ltd. Composition pharmaceutique comprenant un inhibiteur de l'aromatase et un oestrogene convenant a une hormonotherapie substitutive pour un homme
JP2006516084A (ja) * 2002-06-27 2006-06-22 セントカー・インコーポレーテツド Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
MY140723A (en) 2010-01-15
RU2360681C2 (ru) 2009-07-10
CA2513910A1 (fr) 2004-08-19
ZA200506221B (en) 2006-05-31
EP1857111A2 (fr) 2007-11-21
DE602004009288D1 (de) 2007-11-15
EP1589976B1 (fr) 2007-10-03
CY1107816T1 (el) 2013-06-19
CN1747736A (zh) 2006-03-15
KR20050098296A (ko) 2005-10-11
EP1589976A1 (fr) 2005-11-02
DE602004009288T2 (de) 2008-07-10
CA2513910C (fr) 2012-04-03
ATE374612T1 (de) 2007-10-15
KR101075929B1 (ko) 2011-10-26
IS2547B (is) 2009-10-15
US20110009373A1 (en) 2011-01-13
RU2008138166A (ru) 2010-03-27
CN100393360C (zh) 2008-06-11
TWI354556B (en) 2011-12-21
PL214680B1 (pl) 2013-09-30
TW200503731A (en) 2005-02-01
GB0302572D0 (en) 2003-03-12
MXPA05008347A (es) 2005-11-04
CO5580789A2 (es) 2005-11-30
PL377939A1 (pl) 2006-02-20
RU2005127667A (ru) 2006-03-27
UA80741C2 (en) 2007-10-25
JP2011001388A (ja) 2011-01-06
US20060142256A1 (en) 2006-06-29
NZ541222A (en) 2008-12-24
HK1082918A1 (en) 2006-06-23
JP4658918B2 (ja) 2011-03-23
US7910570B2 (en) 2011-03-22
PT1589976E (pt) 2007-11-22
ES2293215T3 (es) 2008-03-16
BRPI0407039A (pt) 2006-01-17
WO2004069260A1 (fr) 2004-08-19
IS8008A (is) 2005-08-30
JP2006516602A (ja) 2006-07-06
DK1589976T3 (da) 2007-12-27
EP1857111A3 (fr) 2009-03-04
IL169583A0 (en) 2007-07-04
AU2004210184B2 (en) 2007-01-04
AU2004210184A1 (en) 2004-08-19
AR043013A1 (es) 2005-07-13

Similar Documents

Publication Publication Date Title
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
DK1322336T3 (da) Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE50312034D1 (de) Liposomale glucocorticoide
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
ATE250077T1 (de) Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
TW200508233A (en) Chk-1 inhibitors
NO20013632L (no) Steroid sulfatase inhibitorer og fremgangsmater for fremstilling og anvendelse av det samme
MXPA04005417A (es) Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis.
NO20044342L (no) Androgent farmasoytisk preparat og fremgangsmate for behandling av depresjon
NO20024735L (no) Anvendelse av fulvestrant for behandling av resistent brystkreft
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
NO20062978L (no) Reduksjon av dermal arrdannelse
NO20044321L (no) Piperazinyl- eller piperidinylamin-sulfaminsyreamider som inhibitorer av steroid sulfatase
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
WO2002062391A3 (fr) Methode d'utilisation d'un inhibiteur de la cyclooxygenase-2 et de steroides sexuels dans une polytherapie pour traiter et prevenir la dysmenorrhee
WO2003059332A3 (fr) Traitement de l'uveite
NO20030606D0 (no) Modifisert gj¶r og anvendelser derav, n¶rmere bestemt for fremstilling avsteroidderivater
FR2812549B1 (fr) Associations dalfopristine/quinupristine avec le cefpirome
UA33294A (uk) Спосіб реабілітації хворих після металоостеосинтезу внутрішньосуглобових переломів.
UA30570A (uk) Спосіб комплексного лікування пародонтиту

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application